Trial Profile
A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen TDS-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Testosterone (Primary) ; Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics
- Acronyms TRANSFERENCE
- Sponsors Transdermal Delivery Solutions Corp
- 12 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 12 Jan 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.
- 30 Nov 2022 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.